Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
about
Use of reflective materials during phototherapy for newborn infants with unconjugated hyperbilirubinaemiaFluid supplementation for neonatal unconjugated hyperbilirubinaemiaChest shielding for prevention of a haemodynamically significant patent ductus arteriosus in preterm infants receiving phototherapyHome- versus hospital-based phototherapy for the treatment of non-haemolytic jaundice in infants at more than 37 weeks' gestationHome versus hospital-based phototherapy for the treatment of non-haemolytic jaundice in infants more than 37 weeks gestationChest shielding for prevention of a haemodynamically symptomatic patent ductus arteriosus in preterm infants receiving phototherapyEffect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomesChinese herbal medicines for the treatment of neonatal jaundiceIntermittent phototherapy versus continuous phototherapy for neonatal jaundiceEffect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomesCysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonatesHigher versus lower amino acid intake in parenteral nutrition for newborn infantsNumbers needed to treat with phototherapy according to American Academy of Pediatrics guidelinesAuditory neuropathy spectrum disorder in late preterm and term infants with severe jaundice.Hyperbilirubinemia in Neonates: Types, Causes, Clinical Examinations, Preventive Measures and Treatments: A Narrative Review ArticleFacility-based constraints to exchange transfusions for neonatal hyperbilirubinemia in resource-limited settingsItalian guidelines for the management and treatment of neonatal cholestasisRecommendations for transfusion therapy in neonatologyBilirubin neurotoxicity in preterm infants: risk and preventionAudiologic impairment associated with bilirubin-induced neurologic damageA pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonatesBattery-free, stretchable optoelectronic systems for wireless optical characterization of the skin.A novel newborn rat kernicterus model created by injecting a bilirubin solution into the cisterna magnaRisk factors for severe neonatal hyperbilirubinemia in low and middle-income countries: a systematic review and meta-analysisUtility of Decision Rules for Transcutaneous Bilirubin MeasurementsApnea in acute bilirubin encephalopathy.Central auditory processing disorder profile in premature and term infants.Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunctionManagement of late-preterm and term infants with hyperbilirubinaemia in resource-constrained settingsSafety and efficacy of filtered sunlight in treatment of jaundice in African neonatesEffects of visible light on the skin.Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise.Management of neonatal hyperbilirubinemia: pediatricians' practices and educational needsAddressing hemolysis in an infant due to mother-infant ABO blood incompatibilitySevere hemolytic disease of the newborn from anti-e.The evaluation of polycythemic newborns: efficacy of partial exchange transfusion.Neonatal morbidity after exchange transfusion for red cell alloimmune hemolytic disease.Exchange transfusion for neonatal hyperbilirubinemia: an 8-year single center experience at a tertiary neonatal intensive care unit in Turkey.Thrombocytopenia in neonates with polycythemia: incidence, risk factors and clinical outcome.
P2860
Q24187410-8C8C9C93-F8FC-4411-8DD0-7464A7F6FD24Q24187463-CCB010E8-9F48-4FC5-A95E-DEEEBF919820Q24187993-6C3486EF-5670-416F-A801-80559791526BQ24194077-3D36DBF9-811C-4D17-95A1-B7A8C167B2BDQ24197805-676317A6-A6F5-475C-93B9-E1AFA1702CDFQ24200802-E666574A-195F-4B58-A2BC-8388408E8FCAQ24201258-BC046818-CA8F-42BF-9267-7E4ED425D509Q24239917-3F1C1A18-E9CE-4B0B-9C03-9F8B5B6581B2Q24240825-90BF1C3D-4DD3-4920-A00C-2EB7025AC401Q24242973-3A738675-404A-456A-9106-2CC91CAC711EQ24243990-A70327D7-E70B-49D3-9752-5AFFA9EEF494Q24244418-D4A2E300-D890-430A-AE8E-1BDE1FA6EEFDQ24617224-3864B7F7-A3B4-4992-9537-269C18CCCB77Q24627971-4DE7FFD0-3665-4F95-A909-E81A1454DDABQ26741363-725FA223-F35C-4F8C-A3D3-8FC4AFC840B1Q26750484-C11A175A-7D39-45A4-99E6-93845CA8B7B4Q26782860-FEB45476-49A1-4E6F-9953-2116BAB3245BQ26786617-5A096149-68E2-498F-B4B3-2EB5666F090DQ26823587-AF8AEB25-E166-45FA-B462-314F08EF2780Q26863579-9DA04F68-805C-4BE6-95BC-C44D0BEFF3ACQ26864442-3922B577-B12E-4D80-A223-4E9111620126Q27333647-0CE6239F-B8C4-4E7C-8CB9-CEDD2B65ED31Q27335001-3791D66E-BB9B-4D87-978A-BEE3FDC24E91Q28083635-4D9CB84B-8C21-4A94-A7FC-C682A49AAD12Q30353014-21551057-596D-44ED-BA37-6F17BCE6E02FQ30400039-0C9A5256-313E-4F2E-B40A-D90D835F6E28Q30416341-4FC6B7D6-064E-42E5-8A51-D87E6C4E55ABQ30445380-82829876-EB0E-478B-8C9F-65C84C5C98E7Q30471494-FC3B5B5E-0584-4B57-BD7A-51E25DFEAD26Q30643500-78C28F11-FE91-4229-AE47-12AB081282E4Q30660621-65582ACB-14F5-42A6-9464-1FC83E80A517Q30840740-3E019484-D671-49B1-A0F1-AD106647849AQ30856047-88DD0D16-1088-42C8-A742-6142A9973F18Q33235592-DA930C5A-1847-4E79-A949-C15726A8A904Q33354980-2EDB7D05-D176-4668-B7FC-A8D8E1E39671Q33378804-6C85FB15-8F02-466F-817A-82338C7D334AQ33393709-C3912488-E879-472C-A73B-29BB02923D56Q33404815-46D63228-3766-409E-B905-78AF796A2E54Q33417459-CAC200AA-476B-489E-B87A-06D08FCB5B58Q33419523-A1F0136D-5194-4AAA-88E6-F4ED6E688582
P2860
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@ast
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@en
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@nl
type
label
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@ast
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@en
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@nl
prefLabel
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@ast
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@en
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@nl
P356
P1433
P1476
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
@en
P2093
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia
P304
P356
10.1542/PEDS.114.1.297
P407
P577
2004-07-01T00:00:00Z